Mankind Pharma Limited — Investor Meet, 09-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Q3 FY26 revenue rose 11.5% to INR 3,567 Cr; 9M revenue increased 18.7% to INR 10,835 Cr. Adjusted EBITDA margin was 25.9% (Q3). Profit after tax grew 9.5% to INR 414 Cr. Net debt reduced to INR 4,294 Cr.

**Management Outlook:** Workforce stability is improving, enabling gradual recovery. Domestic organic growth was 9.1% (ex-OTC), led by strong chronic therapy performance. Acute segments are expected to recover. OTC sales improved sequentially. BSV exports saw double-digit growth. A GLP-1 launch is planned for around March.

**Strategic & Investor Angle:** The company is navigating post-restructuring challenges. Management is confident their unique culture and disciplined execution will restore outperformance and deliver long-term value.